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Background/aim: To evaluate refractive and strabismic results and the efficacy of intravitreal bevacizumab in retinopathy of prematurity
(ROP) ineligible for laser therapy.
Materials and methods: Thirty-nine eyes of 20 consecutive infants with high-risk prethreshold ROP (11 infants with Zone I and 9
infants with Zone II disease) who were ineligible for laser therapy due to systemic and/or ocular conditions were treated with intravitreal
bevacizumab. Recurrent retinopathy was treated with laser ablation. The final follow-up examination was performed at 29.8 ± 6.0
months of corrected age.
Results: All eyes responded to the initial treatment with intravitreal bevacizumab. ROP recurred in 8 eyes (36%) with initial Zone I
disease and in only 2 eyes (11%) with initial Zone II disease, which were successfully treated with laser ablation. No eye developed
myopia higher than 5.0 diopters. At 2.5 years, the Zone I eyes that had received laser treatment appeared to be more myopic than the
Zone I eyes treated only with intravitreal bevacizumab (P = 0.038). A tendency for a higher incidence of strabismus after additional laser
therapy was also noted, but was not significant (P = 0.22).
Conclusion: Avoidance or even deferral of laser ablation with intravitreal bevacizumab may lead to less myopization in ROP compared
with conventional laser treatment.
Key words: Bevacizumab, myopia, retinopathy of prematurity, strabismus, vascular endothelial growth factor.

1. Introduction
Retinopathy of prematurity (ROP) is a neovascular
retinal disorder in premature infants that can lead to
devastating vision complications. The role of vascular
endothelial growth factor (VEGF) in the pathogenesis and
progression of ROP has been well documented (1,2). The
beneficial effects of intravitreal anti-VEGF agents in ROP
management have been shown in previous studies (3–14).
In a randomized and controlled multicenter study of stage
3 ROP with plus disease, intravitreal bevacizumab therapy
appeared to excel conventional laser therapy for Zone I
disease, and had comparable results with laser therapy for
Zone II disease (8).
The major significant disadvantage of intraocular antiVEGF therapy is the possibility of long-term systemic
side effects in infants; even randomized trials do not have
adequate power to provide an evidence-based answer to

this concern. On the other hand, a major advantage of antiVEGF agents over conventional laser is the avoidance of
permanent destruction of the peripheral retina. It provides
a chance for vascularization and salvaging the peripheral
retina and the visual field. The prevalence of high myopia
and strabismus was reported to be higher in premature
infants who develop ROP and was correlated with ROP
severity (15,16). A recent clinical trial has shown less
myopization following intravitreal anti-VEGF treatment
compared with laser treatment for ROP (17). In the
present study, we aimed to report the results of intravitreal
bevacizumab specifically in premature infants ineligible
for laser therapy, with particular emphasis on refractive
and strabismic outcomes. To the best of our knowledge,
strabismic results after intravitreal anti-VEGF treatment
in ROP have not been reported before.

* Preliminary data of this study was presented at the 48th Annual Congress of the Turkish Ophthalmology Society in November 2014
		 in Antalya, Turkey.
** Correspondence: ahondur@gazi.edu.tr
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2. Materials and methods
The study protocol was approved by the Institutional
Ethics Board. Consecutive premature infants with highrisk prethreshold (type 1) ROP (18) who were ineligible
for conventional laser therapy in two major centers
were enrolled and treated with intravitreal injection of
bevacizumab (Avastin; Genentech Inc, San Francisco, CA,
USA). These infants were either systemically too sick to
receive general anesthesia for laser treatment or unable to
undergo laser treatment due to ocular conditions such as
corneal edema, a miotic pupil, or hazy media.
The revised guidelines set forth by the International
Classification for Retinopathy of Prematurity were used
to classify ROP (19). The criterion for enrollment and
treatment was the presence of high-risk prethreshold (type
1) ROP, including stage 3 retinopathy and/or plus disease
in Zone I or stage 2 or 3 retinopathy with plus disease in
Zone II (18). The investigational nature of the treatment
and off-label use of bevacizumab were clearly explained. In
addition, written informed consent was obtained from the
parents of all infants in the study.
Intravitreal injection of bevacizumab was performed
under sterile conditions in the operating room, unless
the general health status of the baby precluded transfer to
the operating room. In such cases, treatment was carried
out in the newborn intensive care unit. All treatments
were performed 1 day after the diagnosis of high-risk
prethreshold disease. After topical anesthesia, a drop of
5% povidone-iodine was placed into the conjunctival sac.
Following treatment of the eyelids with 10% povidoneiodine, a pediatric lid speculum was inserted. The eye was
stabilized with a cotton tip applicator, following which 0.5–
0.625 mg of bevacizumab (0.02–0.025 mL) was injected
intravitreally with a 30-gauge needle 0.5 to 1 mm posterior
to limbus in the superior temporal quadrant. Following
the injection, a drop of antibiotic (0.3% moxifloxacin) was
applied and continued 4 times daily for 3 days.
Each eye was examined daily after treatment until
regression of neovascularization and plus disease was
determined. Thereafter, eyes with Zone I and II disease
were examined weekly and fortnightly, respectively, until
complete vascularization was achieved or a decision for
further treatment with laser was made. No eye received
more than one injection. Recurrent cases of ROP were
treated with near confluent laser ablation.
Follow-up visits included cycloplegic retinoscopy
and evaluation of visual alignment, anterior segment,
and retina. Cycloplegic retinoscopy was conducted
approximately 30 min after two drops of 1% cyclopentolate
hydrochloride were administered 10 min apart. Mean
spherical equivalent refraction was compared using the
Mann–Whitney U test and the proportion of cases with
strabismus was compared using Fisher’s exact test.

3. Results
The study involved 40 eyes of 20 infants (9 girls and 11
boys) with a mean birth weight of 809.2 ± 189.0 g (with a
range of 570–1300 g) and a mean gestational birth age of
25.9 ± 1.7 weeks (with a range of 23–29 weeks). Twentytwo eyes of 11 infants presented with Zone I disease at 33.6
± 1.5 weeks and 18 eyes of 9 infants presented with Zone
II retinopathy at 34.6 ± 2.3 weeks (Table). All eyes had plus
disease. Following intravitreal bevacizumab injection, the
plus disease disappeared in 1 to 3 days and disease stage
regression was documented at 1 or 2 weeks. No intravitreal
bevacizumab injection was performed to the second eye
of 1 infant with Zone I disease as retinopathy in this eye
regressed after injection to the first eye. This eye was
excluded from the study.
No injury to the lens or retina, retinal detachment,
vitreous hemorrhage, or intraocular inflammation
occurred following the injection. Five infants, all except one
with initial Zone I disease, experienced ROP recurrence,
requiring treatment in Zone II at 49.9 ± 7.9 weeks. The
general health and ophthalmological status of these infants
had improved and permitted laser treatment. Following
laser treatment of these 10 eyes, no other complication
occurred and disease regression was documented in these
eyes. The final follow-up examination was performed at
29.8 ± 6.0 months of corrected age (with a range of 12–37
months).
No eye developed myopia higher than 5.0 D. Zone I
and II eyes that had received only intravitreal bevacizumab
treatment did not show any difference in terms of refractive
error during the final visit (P = 0.29). Zone I eyes that
had received the additional laser treatment appeared
to be more myopic than Zone I eyes treated with only
intravitreal bevacizumab (P = 0.037) (Table).
A lower proportion of the cases that received only
intravitreal bevacizumab (2 of 15 cases: 13%) developed
strabismus compared with the cases that received the
additional laser treatments (2 of 5 cases: 40%). However,
the difference was not significant (P = 0.22). The difference
of the proportion of strabismus in cases with Zone I versus
Zone II disease was also insignificant (3 cases (27%)
versus 1 case (11%), respectively, P = 0.31). In addition,
more cases with Zone I disease had additional systemic
pathologies that can be related to strabismus (Table).
4. Discussion
In infants with high-risk prethreshold ROP ineligible for
laser treatment intravitreal bevacizumab appeared to be
effective for both Zone I and Zone II disease. The process
also exhibited favorable refractive results compared with
conventional laser treatment. The beneficial effect of
intravitreal bevacizumab was noted in a few days with
the resolution of plus disease, which was followed by
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Table. Clinical data of the infants.											
			
Eyes with Zone I ROP

Eyes with Zone II ROP

Laser treated

No laser treatment

Total

(Total)

Number of cases (eyes)

4 (8)

7 (13)

11 (21)

9 (18)

Gestational age

25.5 ± 2.5 weeks

26 ± 1.0 weeks

25.4 ± 2.1 weeks

26.1 ± 1.8 weeks

Birth weight

807.5 ± 290.9 g

803.5 ± 96.1 g

805.0 ± 175.8 g

814.4 ± 214.9 g

Corrected age at ROP diagnosis

32.2 ± 1.5 weeks

34.4 ± 0.9 weeks

33.6 ± 1.5 weeks

34.6 ± 2.3 weeks

Cases with additional systemic pathology
Hydrocephaly

2

-

2

-

Intracranial hemorrhage

-

2

2

-

Bronchopulmonary dysplasia

1

2

3

1

Sepsis

-

2

2

-

SE refractive error* (final visit)

–1.2 ± 2.5 D

0.8 ± 1.1 D

0.1 ± 2.0 D

0.4 ± 0.9 D**

Cases with strabismus

2

1

3

1†

SE: spherical equivalent; D: Diopter; *: Mean ± standard deviation; **: The laser-treated 2 eyes of a single infant were excluded; †: In an
infant who did not receive laser treatment.

regression of the disease stage. For Zone II disease, a single
injection seemed to be effective for almost all cases in this
study. However, among eyes with Zone I disease, 8 eyes
(38%) required additional laser treatment about 18 weeks
later. In these eyes, intravitreal bevacizumab served as a
temporizing treatment, giving an opportunity for further
development of the retina into Zone II, and hence allowing
salvaging of more retinal tissue and a larger visual field. In
addition, it gave an opportunity for the general and ocular
health of the infants to improve, which made them eligible
for laser treatment. Overall, 29 eyes (74%) achieved
complete cure with only a single injection of intravitreal
bevacizumab.
The favorable efficacy of intravitreal bevacizumab
therapy for ROP in this patient group is mostly in
accordance with previous reports. However, our
success rate with only a single injection of intravitreal
bevacizumab appears to be lower compared with most
previous studies (3,6,9–12). On the other hand, a few
studies have reported lower success rates comparable with
our results (13,14). Differences in patient characteristics,
neonatal intensive care, study protocol, and reactivation
criteria may be responsible for these dissimilarities. A
significant difference of this study, in terms of patient
characteristics, was the inclusion of only infants ineligible
for laser treatment. The results may be different in the cases
of optional intravitreal bevacizumab treatment for infants
suitable for laser treatment or intravitreal bevacizumab as
salvage treatment when laser treatment has failed.
Another important point to consider in terms of
success after intravitreal anti-VEGF treatment is the
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duration of follow-up. Studies with shorter follow-up
may report higher success rates since eyes that appear
to respond initially may subsequently develop recurrent
disease. Such a phenomenon typically occurs quite late in
the disease course and can progress to retinal detachment
without treatment. Therefore, a prolonged follow-up for
late peripheral retinal changes and reactivation appears to
be mandatory until complete vascularization is achieved or
laser ablation of avascular peripheral retina is performed
(20–22).
Myopia in infants with ROP tends to correlate with
early gestational age, low birth weight, and disease severity
(16,23). In our study, Zone I and II eyes receiving only
intravitreal injection did not reveal any difference in
refraction. Although Zone I eyes would be expected to
have higher myopia, a contradicting outcome was also
observed in a recent report of refractive outcomes of the
BEAT-ROP trial (17). These results may imply that severity
of retinopathy may not be the most important determinant
of myopia in ROP.
Previous studies have also demonstrated that myopia
in ROP correlates with application of ablative treatment.
In the ETROP study, approximately 70% of high-risk
prethreshold ROP eyes were myopic in early childhood
(16,23). In addition, myopization was more significant
in children receiving an invasive cryotherapy than in
children treated with the less invasive laser ablation (24).
Less myopization following intravitreal bevacizumab
compared with laser ablation in ROP was first reported
by Harder et al. (9). In a recent randomized clinical trial,
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intravitreal bevacizumab treatment resulted in about 6.0
and 4.5 D lower myopia compared with conventional
laser treatment in Zone I and II eyes, respectively (17).
In our study, avoidance of laser treatment also appeared
to offer a refractive benefit of less myopization in Zone
I eyes (P = 0.038). However, we could not perform such
a refractive comparison for Zone II eyes because only 1
infant with Zone II disease required laser treatment. In
addition, the refractive benefit of avoiding laser treatment
was only about 2.0 D lower myopia in our study, far less
than that reported in the BEAT-ROP trial (17). However,
our study had a different design: laser ablation was used
as a salvage treatment for recurrent disease and at a later
gestational age. In addition, no eye developed high myopia
(higher than 5.0 D) and even the myopia in Zone I eyes
that received laser was much lower compared with that
following primary laser ablation in other studies (8,17).
This could be due to laser ablation being performed much
later compared with primary laser therapy, thus possibly
salvaging some extent of anterior segment development in
the intervening time (17).
Avoidance of laser treatment did not offer a significant
benefit in terms of strabismus in the present study (P = 0.22).
However, a trend in favor of only anti-VEGF treatment
(13% versus 40%) was observed. A greater proportion
of cases with Zone I disease suffered from strabismus
compared with cases with Zone II disease. However, this

difference was not significant either (P = 0.31). In addition,
central nervous system (CNS) pathologies, namely
hydrocephalus and intracranial hemorrhage, were more
frequent in infants with Zone I disease and could have a
greater effect on strabismus than ROP itself. On the other
hand, less myopization may provide secondary beneficial
outcomes such as a lower possibility of anisometropia and
amblyopia, which are known risk factors for strabismus
in patients with ROP (15). Further research with a
greater number of cases may reveal a beneficial effect of
avoiding laser in terms of strabismus. Nevertheless, the
disclosure of a favorable effect on strabismus appears to be
challenging because CNS pathologies, which are frequent
in infants with ROP, also appear to play an important role
in pathogenesis of strabismus.
In conclusion, intravitreal bevacizumab was an
effective treatment for ROP in infants ineligible for laser
therapy. A single injection seemed to be almost completely
sufficient for eyes with Zone II disease, while in some
eyes with Zone I disease additional laser treatment was
necessary. Nevertheless, intravitreal bevacizumab served
as a temporizing treatment in the eyes that required laser
treatment and gave an opportunity for further development
of the retina and visual field into Zone II. Avoidance or
deferral of laser ablation with intravitreal bevacizumab
treatment seemed to provide less myopization in this
patient group.
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